Summary & Overview

CPT 6150F: IBD Not Receiving First Course of TNF Inhibitor

CPT code 6150F denotes a quality measure identifying patients with inflammatory bowel disease (IBD) who are not receiving a first course of a tumor necrosis factor (TNF) inhibitor. Nationally, this code is used to track adherence to clinical pathways and medication utilization for IBD, inform quality programs, and support payer performance measurement. It matters because TNF inhibitors are a central class of biologic therapies for moderate-to-severe IBD, and monitoring their initiation patterns affects outcomes, utilization, and cost trends across care settings.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical intent and workplace setting, comparative benchmarks where available, and context on how this measure fits into broader quality and utilization reporting. The publication outlines typical sites of service and the service type tied to the code, summarizes implications for quality reporting, and points to areas where policy updates or payer coverage policies commonly intersect with initiation of TNF inhibitor therapy. Data not available in the input is noted where relevant.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareCPT 6150FInflammatory Bowel DiseaseTNF inhibitorQuality measureOutpatient gastroenterologyMedication managementClinical qualityBiologic therapy

Billing Code Overview

CPT code 6150F indicates that a patient with inflammatory bowel disease (IBD) is not receiving a first course of a tumor necrosis factor (TNF) inhibitor. This measure captures the absence of initial TNF inhibitor therapy in the clinical management of IBD.

Service type: Quality measure related to medication management for IBD
Typical site of service: Ambulatory/Outpatient gastroenterology care and other outpatient settings where IBD treatment decisions are made

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with an established diagnosis of inflammatory bowel disease (Crohn disease or ulcerative colitis) who, at a clinic or infusion center visit, is documented as not receiving a first course of a tumor necrosis factor (TNF) inhibitor. The clinical workflow begins with an outpatient gastroenterology encounter where medical history, prior biologic exposure, current disease activity, and prior treatment trials are reviewed. The clinician documents rationale for not initiating a first TNF inhibitor (examples: contraindication, patient preference, planned alternative therapy, prior adverse reaction to other biologic classes, or current enrollment in an alternate therapy trial). Documentation is entered into the medical record, a visit note is coded with the appropriate evaluation and management code, and quality or registry reporting captures 6150F to indicate that a first TNF inhibitor was not administered. The typical site of service is an outpatient gastroenterology clinic or an infusion/infusion-planning area within a hospital outpatient department. Common modifiers applied to associated claims may include 52 (reduced services) and 53 (discontinued procedure) when procedure-level adjustments are required for other billed services during the same encounter.

Coding Specifications

Modifier	Description	When to Use
`52`	Reduced services	Use when a billed procedure or service is partially reduced or not completed as originally planned during the same encounter.
`53`	Discontinued procedure	Use when a procedure is started but terminated due to extenuating circumstances or those that threaten patient safety.
`25`	Significant, separately identifiable E/M service by the same physician on the same day of the procedure	Use when an evaluation and management visit is separately identifiable from other services provided the same day.
`59`	Distinct procedural service	Use to indicate a procedure or service was distinct or independent from other services performed on the same day.
`76`	Repeat procedure by same physician	Use when a procedure is repeated by the same physician subsequent to the original.
`77`	Repeat procedure by another physician	Use when a procedure is repeated by a different physician.
`78`	Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period	Use when an unplanned return to the procedure room occurs for related care.
`GA`	Waiver of liability statement on file (patient declined)	Use when patient refuses a specific therapy and a waiver is documented, relevant when declining TNF inhibitor therapy.
`GQ`	Qualified nonphysician provider service (federally qualified telemedicine)	Use for telehealth services furnished through asynchronous telecommunications.
`95`	Synchronous telemedicine service rendered via real-time interactive audio and video telecommunications system	Use when the encounter documenting non-initiation of a TNF inhibitor occurs via live telehealth.

Taxonomy Code	Specialty	Notes
207RG0100X	Gastroenterology	Board-certified gastroenterologists manage IBD treatment decisions and biologic therapy planning.
207RK0101X	Pediatric Gastroenterology	Pediatric specialists evaluate TNF inhibitor use in children and adolescents with IBD.
363L00000X	Infusion Therapy	Infusion specialists and nursing staff administer biologic therapies and coordinate infusion planning.
207RN0402X	Internal Medicine (Hospitalist)	Hospital-based internists may document decisions about biologic initiation during inpatient stays.
207RH0002X	Colorectal Surgery	Colorectal surgeons collaborate on care when surgical options influence biologic therapy planning.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`K50.90`	Crohn's disease, unspecified, without complications	Common indication for consideration of TNF inhibitor therapy; documentation may state TNF inhibitor is not being started.
`K51.90`	Ulcerative colitis, unspecified, without complications	Common indication for consideration of TNF inhibitor therapy; used when therapy is deferred or not initiated.
`K50.811`	Crohn's disease, ileocolic, with abscess	Active complication that may alter the decision to initiate a TNF inhibitor.
`K51.20`	Ulcerative (chronic) pancolitis, unspecified	Extensive disease often considered for biologic therapy; documentation may state not initiating TNF blocker.
`Z79.899`	Other long term (current) drug therapy	Used when patient is on alternative chronic medication regimens that influence TNF inhibitor decisions.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M code for an outpatient visit where the decision to not start a first TNF inhibitor is documented.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for more complex visits where detailed discussion of biologic options and contraindications occurs.
`96365`	Intravenous infusion, hydration; initial, up to 1 hour	May be billed when an infusion is started for other therapies during the same encounter, relevant if TNF inhibitor is not initiated.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Listed as analogous infusion administration code for biologic agents when initiation occurs; relevant in workflows where TNF inhibitors are given.
`99241`	Office consultation for a new or established patient, typically 15 minutes (office consult)	May be used when specialist consultation documents non-initiation of TNF inhibitor and provides alternative plan.